Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Return on Sales (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Return on Sales for 6 consecutive years, with 7.85% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 2590.0% to 7.85% in Q4 2025 year-over-year; TTM through Dec 2025 was 17.96%, a 1579.0% increase, with the full-year FY2025 number at 17.96%, up 1579.0% from a year prior.
  • Return on Sales was 7.85% for Q4 2025 at Relay Therapeutics, up from 35.52% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 83496.0% in Q4 2023 to a low of 827.66% in Q2 2023.
  • A 5-year average of 4032.65% and a median of 67.83% in 2021 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: surged 8376272bps in 2023, then tumbled -8352975bps in 2024.
  • Relay Therapeutics' Return on Sales stood at 118.97% in 2021, then crashed by -124bps to 266.72% in 2022, then soared by 31405bps to 83496.0% in 2023, then plummeted by -100bps to 33.75% in 2024, then skyrocketed by 77bps to 7.85% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Return on Sales are 7.85% (Q4 2025), 35.52% (Q3 2025), and 103.02% (Q2 2025).